Next generation veterinary biologics

Kedi is pioneering new therapies for cats.

WHAT CATS FACE

Same diseases. Different care.

Veterinary medicine lags decades behind human medicine, and our own experience with this gap motivates us to close it.

We established a platform technology and built large datasets to develop monoclonal antibody and peptide therapies for cats.

See our pipeline →

Cancer
IN CATS
1 in 5 cats are diagnosed with cancer; mostly lymphomas, oral carcinomas, mammary tumors or fibrosarcomas.
CARE
Treatment can involve surgery, radiation, or chemotherapy drugs borrowed from human medicine. Patient prognosis remains poor.
KEDI-01 · KEDI-02
We are developing two antibodies to drastically improve outcomes across the most prevalent types of feline cancer.
Allergy and itch
IN CATS
Cats suffer various allergic or atopic skin conditions, frequently with asthma, but these are poorly understood.
CARE
Antimicrobials and steroids are commonly used in feline dermatology. There are no approved biologic therapies in this area.
KEDI-03
We study feline dermatitis and advance a novel drug mechanism aiming to provide deep and durable relief to patients.
Obesity and diabetes
IN CATS
It is estimated that 30–60% of cats seen by vets are overweight or obese, which is associated with poor health outcomes.
CARE
Care rests on dietary changes and, once diabetes sets in, daily insulin injections or newer oral drugs. Behavioral adaptations are challenging.
KEDI-04
Inspired by GLP-1s, our feline multi-incretin aims to deliver a safe and convenient solution for weight management and diabetes.
Kidney diseases
IN CATS
Feline chronic kidney disease develops silently over years. It is poorly understood, yet is one of the leading causes of death.
CARE
Disease is managed rather than treated. Special diets and fluids can slow it, but a disease-modifying treatment approach is still lacking.
KEDI-05
Based on our own discoveries, we are developing an anti-fibrotic antibody with potential to become a breakthrough therapy.
Pain
IN CATS
Joint diseases (60–90% of older cats) and periodontal issues (>25% of cats) are common causes of pain, which cats hide very well.
CARE
NSAID (e.g. meloxicam) use is very common. Osteoarthritis-associated pain is the only indication with an approved feline monoclonal antibody.
KEDI-06
We built a research program with leading scientists to discover new possibilities for the management of pain with fewer side effects.

Proven drug formats, built natively for cats

Biologic therapies transformed human medicine and gave us a deeper understanding of immunology. Kedi aims to give veterinarians the same precision arsenal to care for our beloved companions.

OUR APPROACH

Monoclonal antibodies

Fc-fusion proteins

More soon…

Species-specific

We develop best-in-class monoclonal antibodies and peptides built on fully feline sequences.

 AI-native

Our data and experimental infrastructure allow us to design and de-risk in tight, iterative loops.

 Ethical

We discover and validate with high ethical standards, and without sacrificing animals.

Built by scientists who care about animals and medicine

We are inspired by mutualism. Kedi envisions and enables biologic R&D that is even more insightful, resource-efficient, and life-sustaining than it is today.

Our vision →   

Meet the team →